Dermatology Among Emerging Rx-To-OTC Switch Categories
This article was originally published in The Rose Sheet
FDA threw the switch floodgates open with the Nonprescription Safe Use Regulatory Expansion (NSURE) initiative and has fueled interest with recent first-in-class switches of Nasacort and Oxytrol for Women. Experts say likely categories for successful switches include dermatology, as drugs for treating eczema, acne and other skin conditions typically do not have systemic effects and address ailments that are readily recognized and understood by consumers.
You may also be interested in...
FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
The market for specialized dermocosmetics is expanding rapidly as big beauty marketers join the fray with products containing OTC-approved drug ingredients for hair and skin care, says Euromonitor Beauty & Personal Care analyst Nicholas Micallef. Coal tar, ketoconazole and salicylic acid are among approved drug ingredients increasingly making their way into beauty.
FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.